CLBT vs GTLB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CLBT shows bullish fundamentals based on deterministic rules. Financial strength is strong (F-Score 7/9). Key strengths include strong valuation and growth metrics. Price trades at a 370.1% premium to fair value estimate ($3.01), limiting near-term upside from a valuation perspective.
GTLB exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, placing it in the 'Weak' health category. Despite strong gross margins of 87.38% and consistent revenue growth of 23.2%, the company is struggling with negative profitability and a catastrophic price collapse (-54.8% over the last year). Heavy insider selling totaling $59.19M and a technical trend score of 0/100 further reinforce a bearish outlook, suggesting that the current price decline may not yet have found a definitive floor despite analyst buy recommendations.
Compare Another Pair
Related Comparisons
CLBT vs GTLB: Head-to-Head Comparison
This page compares Cellebrite DI Ltd. (CLBT) and GitLab Inc. (GTLB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.